The patent on semaglutide expired in India on March 21, 2026, opening the floodgates for dozens of affordable generic versions of the blockbuster GLP-1 drug behind Ozempic and Wegovy, with major Indian pharma companies like Cipla, Sun Pharma, Dr Reddy’s, Biocon, Zydus and others set to launch branded generics at ₹3,000–5,000 per month. மார்ச் 21, 2026 அன்று இந்தியாவில் செமாக்ளூடைடு பேட்டன்ட் காலாவ
Read more
Share with:
